Crispr Therapeutics price target lowered to $78 from $79 at BofA

BofA lowered the firm’s price target on Crispr Therapeutics (CRSP) to $78 from $79 and keeps a Buy rating on the shares. The firm slightly reduced its estimate of collaboration revenues for full-year 2025 and 2026 given the delay from cell collection to booking revenues, but remains positive on the launch potential this year, the analyst tells investors in an earnings preview for its small-to-mid cap biotech coverage.